<- Go Home
Tricida, Inc.
On June 12, 2023, Tricida, Inc went out of business as per its Chapter 11 liquidation filing under bankruptcy. Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Market Cap
$580.00
Volume
450.8K
Cash and Equivalents
$17.7M
EBITDA
-$124.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$13.85
52 Week Low
$0.00
Dividend
N/A
Price / Book Value
-0.00
Price / Earnings
-0.00
Price / Tangible Book Value
-0.00
Enterprise Value
$127.8M
Enterprise Value / EBITDA
-1.06
Operating Income
-$124.3M
Return on Equity
199.58%
Return on Assets
-60.11
Cash and Short Term Investments
$80.2M
Debt
$208.0M
Equity
-$136.1M
Revenue
N/A
Unlevered FCF
-$62.6M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium